Clinical Journal of the American Society of Nephrology
Effects and Safety of Henagliflozin on Cardiac Structure in Dialysis Patients with Heart Failure with Preserved Ejection Fraction
Background Few effective drug treatments exist for dialysis patients with heart failure with preserved ejection fraction (HFpEF). This study aimed to evaluate the effects of henagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on cardiac structure, and its safety in such population. Methods In this multicenter, randomized, double-blind, placebo-controlled trial, dialysis patients with HFpEF were randomly assigned (1:1) to receive henagliflozin or placebo for 24 weeks. All enrolled participants receive …